Ilyang Pharm Asset Resilience Ratio
Ilyang Pharm asset resilience ratio. Ilyang Pharm (007570) has an Asset Resilience Ratio of 2.46% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ilyang Pharm defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ilyang Pharm (2002–2024)
Asset resilience ratio of Ilyang Pharm from 2002 to 2024. This chart shows how Ilyang Pharm's Asset Resilience Ratio has changed over time. Read total liabilities of Ilyang Pharm for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ilyang Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Ilyang Pharm.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.93 Billion | 2.46% |
| Total Liquid Assets | ₩10.93 Billion | 2.46% |
Asset Resilience Insights
- Limited Liquidity: Ilyang Pharm maintains only 2.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ilyang Pharm Industry Peers by Asset Resilience Ratio
Compare Ilyang Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Ilyang Pharm Asset Resilience Ratio by Year (2002–2024)
Ilyang Pharm asset resilience ratio by year from 2002 to 2024. The table below shows the annual Asset Resilience Ratio data for Ilyang Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.97% | ₩8.49 Billion ≈ $5.76 Million |
₩431.21 Billion ≈ $292.23 Million |
+0.07pp |
| 2023-12-31 | 1.90% | ₩6.78 Billion ≈ $4.59 Million |
₩356.66 Billion ≈ $241.70 Million |
+0.81pp |
| 2022-12-31 | 1.09% | ₩5.42 Billion ≈ $3.67 Million |
₩498.19 Billion ≈ $337.61 Million |
-5.86pp |
| 2021-12-31 | 6.95% | ₩34.34 Billion ≈ $23.27 Million |
₩494.27 Billion ≈ $334.96 Million |
+6.89pp |
| 2020-12-31 | 0.06% | ₩270.87 Million ≈ $183.56K |
₩439.12 Billion ≈ $297.58 Million |
+0.05pp |
| 2019-12-31 | 0.01% | ₩43.52 Million ≈ $29.49K |
₩437.46 Billion ≈ $296.46 Million |
-1.25pp |
| 2018-12-31 | 1.26% | ₩5.46 Billion ≈ $3.70 Million |
₩432.25 Billion ≈ $292.93 Million |
+0.51pp |
| 2017-12-31 | 0.76% | ₩3.31 Billion ≈ $2.24 Million |
₩436.37 Billion ≈ $295.72 Million |
+0.75pp |
| 2016-12-31 | 0.01% | ₩43.85 Million ≈ $29.72K |
₩431.26 Billion ≈ $292.26 Million |
-0.07pp |
| 2015-12-31 | 0.08% | ₩354.85 Million ≈ $240.48K |
₩431.63 Billion ≈ $292.51 Million |
-0.06pp |
| 2014-12-31 | 0.14% | ₩594.84 Million ≈ $403.12K |
₩430.83 Billion ≈ $291.97 Million |
0.00pp |
| 2013-12-31 | 0.14% | ₩558.29 Million ≈ $378.34K |
₩398.38 Billion ≈ $269.98 Million |
-0.40pp |
| 2009-12-31 | 0.54% | ₩1.56 Billion ≈ $1.06 Million |
₩289.86 Billion ≈ $196.44 Million |
-7.55pp |
| 2004-12-31 | 8.09% | ₩15.41 Billion ≈ $10.44 Million |
₩190.53 Billion ≈ $129.12 Million |
+3.53pp |
| 2003-12-31 | 4.56% | ₩7.67 Billion ≈ $5.20 Million |
₩168.29 Billion ≈ $114.05 Million |
+1.37pp |
| 2002-12-31 | 3.19% | ₩5.56 Billion ≈ $3.76 Million |
₩174.24 Billion ≈ $118.08 Million |
-- |
About Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more